Skip to main content
SpringerLink
Log in

Methyl-aminolevulinate [Metvix] photodynamic therapy (PDT) will be fully reimbursed in Sweden.

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. PhotoCure.Metvix photodynamic therapy receives full reimbursement for premalignant skin cancer and skin cancer in Sweden. Media Release: 22 May 2008. Available from: URL: http://www.photocure.no

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Methyl-aminolevulinate [Metvix] photodynamic therapy (PDT) will be fully reimbursed in Sweden.. Pharmacoecon. Outcomes News 554, 9 (2008). https://doi.org/10.2165/00151234-200805540-00025

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805540-00025

Keywords

Search

Navigation